Refractory juvenile idiopathic arthritis: using autologous stem cell transplantation as a treatment strategy.
Cellular immune therapy for severe autoimmune diseases can now be considered when such patients are refractory to conventional treatment. The use of autologous stem cell transplantation (ASCT) to treat human autoimmune diseases has been initiated following promising results in a variety of animal models. Anecdotal observations have been made of autoimmune disease remission in patients who have undergone allogeneic bone marrow transplantation as a result of coincidental haematological malignancies. The possibility of inducing immunological self-tolerance by ASCT is particularly attractive as a means for treating juvenile idiopathic arthritis (JIA). In this disease, ASCT restores self-tolerance both through a cell-intrinsic mechanism, involving the reprogramming of autoreactive T cells, and through a cell-extrinsic mechanism, involving a renewal of the immune balance between CD4+CD25+ regulatory T cells and other T cells. This review describes the clinical results of ASCT performed for this disease and the possible underlying immunological mechanisms.
Wulffraat
Nico M
NM
Department of Pediatric Immunology, University Medical Center Utrecht, Wilhelmina Children's Hospital, 3508 AB Utrecht, The Netherlands. n.wulffraat@umcutrecht.nl
de Kleer
Ismé M
IM
Prakken
Berent
B
D000818:Animals; D001171:Arthritis, Juvenile / Q000276:immunology / Q000601:surgery*; D006801:Humans; D012075:Remission, Spontaneous; D033581:Stem Cell Transplantation; D014182:Transplantation, Autologous; D016896:Treatment Outcome